ProFound Therapeutics is at the forefront of expanding our understanding of the human proteome, challenging the long-held belief that only a small fraction of the human genome is translated into proteins. By focusing on the translatome—the complete set of RNA sequences that are translated into proteins—the company has uncovered that a significant portion of the human genome, previously thought to be non-coding, is indeed transcribed into RNA. This insight has led to the identification of tens of thousands of novel proteins, which could serve as new therapeutic targets and drug candidates, thereby opening up a vast array of possibilities for medical intervention across various diseases.

Central to ProFound's innovative approach is their proprietary ProFoundry™ Platform, which utilizes advanced computational techniques and machine learning to rapidly discover and validate new proteins and their functions. The platform employs RiboSeq technology to identify all actively translated RNAs from any genomic region, including those not previously recognized as coding for proteins. By analyzing over a trillion data points, ProFound has created a comprehensive database that catalogs these novel proteins, their biological roles, and their potential therapeutic relevance. This systematic approach not only accelerates the identification of promising drug targets but also enhances the understanding of the molecular mechanisms underlying health and disease, ultimately aiming to develop first-in-class medicines.

United States

ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company’s ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

ProFound Therapeutics

Company Details